Condition: Amyotrophic Lateral Sclerosis (ALS) · Parkinson Disease (PD) · Alzheimer Disease (AD) · Sponsor: Ashvattha Therapeutics, Inc.
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
This description comes directly from the study's public registry record.
Julee Cheung · 408-476-4172 · jcheung@avttx.com
Always discuss trial participation with your own doctor first.
| UCSF | San Francisco, California, United States | Recruiting |
| Stanford University | Stanford, California, United States | Recruiting |
| Mayo Clinic Jacksonville | Jacksonville, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05395624